643,770 Shares in Corteva, Inc. (NYSE:CTVA) Purchased by Albar Capital Partners LLP

Albar Capital Partners LLP acquired a new position in Corteva, Inc. (NYSE:CTVA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 643,770 shares of the company's stock, valued at approximately $36,669,000. Corteva comprises about 8.8% of Albar Capital Partners LLP's portfolio, making the stock its 4th biggest position. Albar Capital Partners LLP owned about 0.09% of Corteva as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. World Investment Advisors LLC bought a new position in shares of Corteva during the third quarter valued at about $319,000. Wilmington Savings Fund Society FSB lifted its stake in shares of Corteva by 247.9% in the third quarter. Wilmington Savings Fund Society FSB now owns 44,080 shares of the company's stock worth $2,591,000 after buying an additional 31,411 shares in the last quarter. Franklin Resources Inc. lifted its stake in Corteva by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 14,788,607 shares of the company's stock valued at $860,746,000 after acquiring an additional 856,007 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Corteva by 6.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,605,608 shares of the company's stock valued at $270,764,000 after buying an additional 288,885 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Corteva by 18.8% during the 4th quarter. GAMMA Investing LLC now owns 13,099 shares of the company's stock valued at $746,000 after purchasing an additional 2,070 shares during the period. Institutional investors own 81.54% of the company's stock.

Insider Buying and Selling

In other news, insider Brian Titus sold 26,560 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $63.74, for a total value of $1,692,934.40. Following the completion of the sale, the insider now directly owns 11,347 shares of the company's stock, valued at approximately $723,257.78. This represents a 70.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.14% of the company's stock.

Corteva Stock Down 0.3 %

Shares of NYSE:CTVA traded down $0.18 during trading on Monday, hitting $62.45. The company's stock had a trading volume of 2,127,679 shares, compared to its average volume of 3,312,547. The company has a market capitalization of $42.65 billion, a PE ratio of 48.41, a PEG ratio of 1.68 and a beta of 0.72. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.93 and a current ratio of 1.45. The stock's 50-day moving average price is $60.60 and its two-hundred day moving average price is $60.58. Corteva, Inc. has a fifty-two week low of $50.01 and a fifty-two week high of $66.24.

Corteva (NYSE:CTVA - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.34 by ($0.02). Corteva had a return on equity of 7.19% and a net margin of 5.36%. As a group, sell-side analysts expect that Corteva, Inc. will post 2.96 EPS for the current year.

Corteva Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 2nd will be paid a dividend of $0.17 per share. The ex-dividend date is Monday, June 2nd. This represents a $0.68 dividend on an annualized basis and a yield of 1.09%. Corteva's payout ratio is currently 52.71%.

Wall Street Analyst Weigh In

A number of brokerages have commented on CTVA. Barclays upped their price target on Corteva from $62.00 to $64.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 21st. Wells Fargo & Company boosted their target price on shares of Corteva from $67.00 to $73.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. Oppenheimer boosted their price objective on Corteva from $70.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, February 7th. Citigroup raised their price objective on Corteva from $69.00 to $74.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Finally, BNP Paribas raised Corteva to a "hold" rating in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $68.43.

About Corteva

Corteva, Inc operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.